PGI1 Systematic Review and Network Meta-Analysis of Infliximab, Adalimumab, Golimumab, Vedolizumab, Andtofacitinib for Moderate-to-Severe Ulcerative Colitis in ANTI-TNF-ALPHA-Naive Patients
Abstract
Authors
S. Takahashi K. Yamabe